How to Successfully Extend the Cash Runway to Growth in Early Commercial Stage Life Science Companies
By ,

This article is the second in a 4-part series reviewing financing solutions for the Life Science sector. Life Science venture capital and private equity-funded startups are constantly chasing capital to extend operating cash runways, driving value inflection milestones such as clinical trial data and funding growth for commercial-stage entities. Understandably,…Read More

Read More
Trends in Financing in Life Sciences: 2024 Updates
By

This article is first in a 4-part series reviewing financing solutions for the Life Science sector. As we move into Q2 of 2024, the Fed continues to hold the line on interest rate declines. Capital markets remain tight and for companies in need of growth financing, this is problematic. This…Read More

Read More
Raising Capital in Life Sciences in 2022-2023: What Works?
By

Raising money in the capital markets for a biopharma or life sciences company over the last few years has been quite a roller coaster ride. Funding among U.S. biotech startups reached a record high of $77 billion in 2021 (Crunchbase), as investors were attracted to expanding opportunities in genetics, therapeutics…Read More

Read More
Fundraising Choices in Life Sciences: What, When & Why?
By

This article is the second in a two-part series about fundraising strategies for life science companies. In our last article, A Menu of Financing Alternatives for Life Science Companies, we looked at the continuum of choices available to life science companies who are actively engaged in fundraising to power up…Read More

Read More